Melius initiates Starbucks stock coverage with Sell rating, $80 price target

Melius Research initiated coverage on Starbucks (SBUX) with a Sell rating and an $80 price target, citing the stock's high valuation (34.6x P/E) and concerns over a prolonged path to operational consistency and brand revitalization, particularly given intense competition in China and ongoing U.S. stabilization efforts. This bearish outlook contrasts with recent reports of Starbucks exploring a potential $10 billion stake sale in its China business and more optimistic analyst views from Stifel and Citi, which have raised price targets to $105 and $100 respectively, anticipating strong U.S. same-store sales and benefits from strategic initiatives.

Analysis

Starbucks (SBUX) presents a dichotomous investment profile, marked by a sharp divergence in analyst sentiment and significant potential corporate actions. On the bearish side, Melius Research has initiated coverage with a Sell rating and an $80 price target, citing a high P/E ratio of 34.6x and significant execution risk. The firm argues that the path to brand revitalization and operational consistency will be longer and more difficult than the market anticipates, pointing to the U.S. business being in a mere stabilization phase and facing intense local competition in the critical China market. Contrasting this view, Stifel and Citi have issued more optimistic outlooks, raising their price targets to $105 and $100, respectively. Their bullish theses are predicated on near-term catalysts, including expectations for strong U.S. same-store sales driven by initiatives like 'Green Apron' and the potential value unlocked by securing a strategic partner in China. This is substantiated by reports that Starbucks is exploring the sale of a stake in its China operations, an asset potentially valued at up to $10 billion, with notable interest from private equity firms such as Carlyle Group and KKR. The situation creates a classic bull-bear standoff, where the stock's valuation appears stretched to some, while others see strategic maneuvers that could crystallize value and accelerate growth.

Key Decisions for Investors

• Investors should weigh the fundamental execution risks and high valuation highlighted by Melius against the potential near-term catalysts from a China strategic partnership and strong U.S. same-store sales.
• Monitor the upcoming earnings report closely for U.S. sales figures and any management commentary on the China stake sale, as these will serve as key validation points for either the bull or bear thesis.
• Given the wide dispersion in analyst price targets ($80 vs. $105), consider strategies that account for elevated uncertainty, such as adjusting position size or using options to hedge against a significant move in either direction pending further clarity.